Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBM-009
- Development stage
- Preclinical
- Lead developer
- Ribomic
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RBM-009 is an aptamer-based therapeutic candidate developed by Ribomic for the treatment of severe asthma. It is designed to target ST2 (also known as Interleukin-1 receptor-like 1), which is the receptor for the cytokine IL-33. By binding to ST2, RBM-009 aims to block or modulate the IL-33/ST2 signaling pathway, a key driver of Type 2 (T2) inflammation and airway hyperresponsiveness in asthma. The drug is currently in the preclinical stage of development and utilizes Ribomic's proprietary RiboART platform for aptamer discovery.
- Other names
- ST2 aptamerST-2 aptamerST 2 aptamer
02
Targets
IL1RL1 (Interleukin 1 receptor-like 1 protein)
Beyond the preview
Go deeper on RBM-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBM-009.